Where it trades today
trading 91% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- RVTY trades at 69.0x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 45.8%, above the sector norm of 22.0%, so position sizing matters more than usual.
- RVTY is in a bullish short-term regime and only 4.1% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- RVTY is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The risk profile looks balanced enough for a diversified core-plus portfolio, provided the position size reflects sector concentration.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in RVTY.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for RVTY come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for RVTY. Last refresh: Sep 18, 2026, 10:57 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Revvity Inc. does
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable…
What analysts expect
RVTY carries a buy consensus from 17 analysts, with an average price target of $126.12 versus $143.45 today (-12.1%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
RVTY generated $2.91B in trailing revenue (1.3% year over year), with a 8.2% net margin, and $604.99M of free cash flow, against $2.32B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $2.86B | $1.56B | $356.63M | $241.20M | $2.15 | $509.41M |
| 2024 | $2.76B | $1.54B | $346.74M | $270.38M | $2.24 | $541.65M |
| 2023 | $2.75B | $1.54B | $300.56M | $693.09M | $5.62 | $9.90M |
| 2022 | $3.31B | $1.99B | $742.70M | $569.18M | $4.59 | $594.18M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
RVTY beside the healthcare names it is usually measured against.
What the chart is saying
Revvity Inc. trades at $143.45, 4.1% below its 52-week high. With a beta of 1.09, it shows about average sensitivity to what the wider market does.
Questions people ask about it
Is RVTY a good buy right now?
Revvity Inc. trades at 69.0x earnings. This is above market average, reflecting growth expectations. Current risk level is High based on 45.8% volatility.
Does RVTY pay dividends?
Yes, Revvity Inc. offers a dividend yield of 0.19%. That is roughly $0.27 per share a year.
How volatile is RVTY?
With 30-day annualized volatility of 45.8% and beta of 1.09, RVTY is classified as High risk. Expect larger swings than the broader market during volatile periods.
What is the analyst price target for RVTY?
The average analyst price target for Revvity Inc. (RVTY) is $126.12 based on 17 analyst estimates, about 12.1% below the current price of $143.45. The published range runs from $100.00 to $165.00.
How much revenue does RVTY generate?
Revvity Inc. reported $2.91B in trailing twelve-month revenue. Revenue growth is running at 1.3% year over year. Net margin sits at 8.2%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.